On the public citation graph

Fragment‐based drug discovery as alternative strategy to the drug development for neglected diseases

https://doi.org/10.1111/cbdd.13030
0 signed · 96 inferred · view as graph

Inferred edges come from two machine sources: sweeps of open repository metadata (mostly SSRN and Zenodo), and a bulk OpenAlex citation snapshot. Every row below is labelled with the one it came from. Neither is a complete citation index — absence here is not evidence of absence.

Is this your work? Sign in with ORCID and put your name on the claims that are yours.
Claim with ORCID
Reference health. See whether every reference in this work resolves to a known work and none has been retracted — and get a dated CiteStamped badge you can embed.
See reference health

What this work says

Outgoing claims: the papers this work cites, builds on, or argues with.

inferredcites →https://doi.org/10.1002/anie.201506783openalex-snapshot
Opportunity Knocks: Organic Chemistry for Fragment‐Based Drug Discovery (FBDD)
inferredcites →https://doi.org/10.1002/cbic.201200521openalex-snapshot
Using a Fragment‐Based Approach To Target Protein–Protein Interactions
inferredcites →https://doi.org/10.1007/s10822-009-9284-1openalex-snapshot
The multiple roles of computational chemistry in fragment-based drug design
inferredcites →https://doi.org/10.1007/s10822-009-9310-3openalex-snapshot
Herman Skolnik award symposium honoring Yvonne Martin
inferredcites →https://doi.org/10.1007/s10822-011-9418-0openalex-snapshot
Structure-guided fragment-based in silico drug design of dengue protease inhibitors
inferredcites →https://doi.org/10.1007/s11030-015-9592-4openalex-snapshot
Fragment virtual screening based on Bayesian categorization for discovering novel VEGFR-2 scaffolds
inferredcites →https://doi.org/10.1016/j.antiviral.2014.03.013openalex-snapshot
Assessment of Dengue virus helicase and methyltransferase as targets for fragment-based drug discovery
inferredcites →https://doi.org/10.1016/j.biochi.2012.02.002openalex-snapshot
Fragment-based design of small RNA binders: Promising developments and contribution of NMR
inferredcites →https://doi.org/10.1016/j.bmc.2006.06.024openalex-snapshot
Drug Guru: A computer software program for drug design using medicinal chemistry rules
inferredcites →https://doi.org/10.1016/j.bmc.2010.05.077openalex-snapshot
Virtual fragment screening for novel inhibitors of 6-phosphogluconate dehydrogenase
inferredcites →https://doi.org/10.1016/j.bmcl.2011.06.067openalex-snapshot
Optimization of a pyrazole hit from FBDD into a novel series of indazoles as ketohexokinase inhibitors
inferredcites →https://doi.org/10.1016/j.bmcl.2013.03.028openalex-snapshot
Learning from our mistakes: The ‘unknown knowns’ in fragment screening
inferredcites →https://doi.org/10.1016/j.bmcl.2015.08.074openalex-snapshot
Identification of non-peptidic cysteine reactive fragments as inhibitors of cysteine protease rhodesain
inferredcites →https://doi.org/10.1016/j.cbpa.2011.02.020openalex-snapshot
Ligand specificity, privileged substructures and protein druggability from fragment-based screening
inferredcites →https://doi.org/10.1016/j.chembiol.2012.10.015openalex-snapshot
HTS by NMR of Combinatorial Libraries: A Fragment-Based Approach to Ligand Discovery
inferredcites →https://doi.org/10.1016/j.clinthera.2014.05.004openalex-snapshot
Measuring Progress in Neglected Disease Drug Development
inferredcites →https://doi.org/10.1016/j.drudis.2007.08.005openalex-snapshot
Integration of fragment screening and library design
inferredcites →https://doi.org/10.1016/j.drudis.2009.03.009openalex-snapshot
Transforming fragments into candidates: small becomes big in medicinal chemistry
inferredcites →https://doi.org/10.1016/j.drudis.2011.08.002openalex-snapshot
The role of fragment-based and computational methods in polypharmacology
inferredcites →https://doi.org/10.1016/j.drudis.2012.03.014openalex-snapshot
Fluorine local environment: from screening to drug design
inferredcites →https://doi.org/10.1016/j.pbiomolbio.2014.08.004openalex-snapshot
Advantages of crystallographic fragment screening: Functional and mechanistic insights from a powerful platform for efficient drug discovery
inferredcites →https://doi.org/10.1016/j.pbiomolbio.2014.09.007openalex-snapshot
Efficient exploration of chemical space by fragment-based screening
inferredcites →https://doi.org/10.1016/j.pharmthera.2016.07.003openalex-snapshot
The ways and means of fragment-based drug design
inferredcites →https://doi.org/10.1016/j.pt.2012.12.005openalex-snapshot
Drug resistance in African trypanosomiasis: the melarsoprol and pentamidine story
inferredcites →https://doi.org/10.1016/j.sbi.2010.04.003openalex-snapshot
Structural biology in fragment-based drug design
inferredcites →https://doi.org/10.1016/j.tips.2012.03.005openalex-snapshot
Structural approaches to obtain kinase selectivity
inferredcites →https://doi.org/10.1016/s1359-6446(03)02831-9openalex-snapshot
A ‘Rule of Three’ for fragment-based lead discovery?
inferredcites →https://doi.org/10.1016/s2214-109x(13)70078-0openalex-snapshot
The drug and vaccine landscape for neglected diseases (2000–11): a systematic assessment
inferredcites →https://doi.org/10.1021/acs.jmedchem.5b01769openalex-snapshot
An NMR Biochemical Assay for Fragment-Based Drug Discovery: Evaluation of an Inhibitor Activity on Spermidine Synthase of Trypanosoma cruzi
inferredcites →https://doi.org/10.1021/bi3005126openalex-snapshot
Fragment-Based Approaches in Drug Discovery and Chemical Biology
inferredcites →https://doi.org/10.1021/ci060094hopenalex-snapshot
Recore: A Fast and Versatile Method for Scaffold Hopping Based on Small Molecule Crystal Structure Conformations
inferredcites →https://doi.org/10.1021/ci200357yopenalex-snapshot
CrystalDock: A Novel Approach to Fragment-Based Drug Design
inferredcites →https://doi.org/10.1021/ci400632yopenalex-snapshot
Increasing the Coverage of Medicinal Chemistry-Relevant Space in Commercial Fragments Screening
inferredcites →https://doi.org/10.1021/ci700424bopenalex-snapshot
Fragment-Based de Novo Ligand Design by Multiobjective Evolutionary Optimization
inferredcites →https://doi.org/10.1021/ja905029topenalex-snapshot
Ligand Mapping on Protein Surfaces by the 3D-RISM Theory: Toward Computational Fragment-Based Drug Design
inferredcites →https://doi.org/10.1021/jm00064a003openalex-snapshot
GroupBuild: a fragment-based method for de novo drug design
inferredcites →https://doi.org/10.1021/jm0492296openalex-snapshot
LEA3D: A Computer-Aided Ligand Design for Structure-Based Drug Design
inferredcites →https://doi.org/10.1021/jm060429mopenalex-snapshot
Using Fragment Cocktail Crystallography To Assist Inhibitor Design of Trypanosoma brucei Nucleoside 2-Deoxyribosyltransferase
inferredcites →https://doi.org/10.1021/jm060511hopenalex-snapshot
Fragment-Based Drug Design: How Big Is Too Big?
inferredcites →https://doi.org/10.1021/jm100060bopenalex-snapshot
Discovery of (2,4-Dihydroxy-5-isopropylphenyl)-[5-(4-methylpiperazin-1-ylmethyl)-1,3-dihydroisoindol-2-yl]methanone (AT13387), a Novel Inhibitor of the Molecular Chaperone Hsp90 by Fragment Based Drug Design
inferredcites →https://doi.org/10.1021/jm100496jopenalex-snapshot
Ligand Specificity in Fragment-Based Drug Design
inferredcites →https://doi.org/10.1021/jm2010332openalex-snapshot
Rational Approaches to Improving Selectivity in Drug Design
inferredcites →https://doi.org/10.1021/jm400362bopenalex-snapshot
Drug Discovery for Neglected Diseases: Molecular Target-Based and Phenotypic Approaches
inferredcites →https://doi.org/10.1021/jm8000373openalex-snapshot
Recent Developments in Fragment-Based Drug Discovery
inferredcites →https://doi.org/10.1021/jm900414xopenalex-snapshot
One Scaffold, Three Binding Modes: Novel and Selective Pteridine Reductase 1 Inhibitors Derived from Fragment Hits Discovered by Virtual Screening
inferredcites →https://doi.org/10.1021/jm901137jopenalex-snapshot
New Substructure Filters for Removal of Pan Assay Interference Compounds (PAINS) from Screening Libraries and for Their Exclusion in Bioassays
inferredcites →https://doi.org/10.1021/jm901723zopenalex-snapshot
Entropic Contribution to the Linking Coefficient in Fragment Based Drug Design: A Case Study
inferredcites →https://doi.org/10.1038/513481aopenalex-snapshot
Chemistry: Chemical con artists foil drug discovery
inferredcites →https://doi.org/10.1038/nature03579openalex-snapshot
An inhibitor of Bcl-2 family proteins induces regression of solid tumours
inferredcites →https://doi.org/10.1038/nchem.217openalex-snapshot
The rise of fragment-based drug discovery
inferredcites →https://doi.org/10.1038/nchembio.1206openalex-snapshot
The why and how of phenotypic small-molecule screens
inferredcites →https://doi.org/10.1038/nm.3048openalex-snapshot
ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets
inferredcites →https://doi.org/10.1038/nrd.2016.109openalex-snapshot
Twenty years on: the impact of fragments on drug discovery
inferredcites →https://doi.org/10.1038/nrd2220openalex-snapshot
A decade of fragment-based drug design: strategic advances and lessons learned
inferredcites →https://doi.org/10.1038/nrd3926openalex-snapshot
Fragment-based lead discovery grows up
inferredcites →https://doi.org/10.1039/c5ob02461gopenalex-snapshot
Design and synthesis of dihydroisoquinolones for fragment-based drug discovery (FBDD)
inferredcites →https://doi.org/10.1073/pnas.0711741105openalex-snapshot
Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity
inferredcites →https://doi.org/10.1093/bib/bbr011openalex-snapshot
Old friends in new guise: repositioning of known drugs with structural bioinformatics
inferredcites →https://doi.org/10.1107/s1399004715007683openalex-snapshot
A binding hotspot in Trypanosoma cruzi histidyl-tRNA synthetase revealed by fragment-based crystallographic cocktail screens
inferredcites →https://doi.org/10.1111/cbdd.12631openalex-snapshot
Considerations of Protein Subpockets in Fragment‐Based Drug Design
inferredcites →https://doi.org/10.1111/j.1476-5381.2010.01127.xopenalex-snapshot
Principles of early drug discovery
inferredcites →https://doi.org/10.1111/j.1582-4934.2008.00665.xopenalex-snapshot
Docking, virtual high throughput screening and in silico fragment‐based drug design
inferredcites →https://doi.org/10.1177/1087057113506118openalex-snapshot
Neoclassic Drug Discovery: The Case for Lead Generation Using Phenotypic and Functional Approaches
inferredcites →https://doi.org/10.1177/1087057114549735openalex-snapshot
Fragment-Based Screening in Tandem with Phenotypic Screening Provides Novel Antiparasitic Hits
inferredcites →https://doi.org/10.1177/1087057114559907openalex-snapshot
Novel Therapeutic Approaches for Neglected Infectious Diseases
inferredcites →https://doi.org/10.1186/1756-3305-3-15openalex-snapshot
The development of drugs for treatment of sleeping sickness: a historical review
inferredcites →https://doi.org/10.1186/1758-2946-4-20openalex-snapshot
Mining collections of compounds with Screening Assistant 2
inferredcites →https://doi.org/10.1186/2049-9957-3-21openalex-snapshot
Global burden, distribution, and interventions for infectious diseases of poverty
inferredcites →https://doi.org/10.1517/17460440903317580openalex-snapshot
Advances in fragment-based drug discovery platforms
inferredcites →https://doi.org/10.1517/17460441.2016.1160883openalex-snapshot
Novel drug discovery for Chagas disease
inferredcites →https://doi.org/10.18632/oncotarget.4968openalex-snapshot
Fragments and hot spots in drug discovery
inferredcites →https://doi.org/10.2174/156802611795429176openalex-snapshot
Finding New Hits in Neglected Disease Projects: Target or Phenotypic Based Screening?
inferredcites →https://doi.org/10.2174/1574891x11666161024165304openalex-snapshot
Targets and Patented Drugs for Chemotherapy of Chagas Disease in the Last 15 Years-Period
inferredcites →https://doi.org/10.3390/ijms131012857openalex-snapshot
Fragment-Based Screening by Protein Crystallography: Successes and Pitfalls
inferredcites →https://doi.org/10.3390/molecules21070860openalex-snapshot
Applications of 19F-NMR in Fragment-Based Drug Discovery
inferredcites →https://doi.org/10.4155/fmc.11.92openalex-snapshot
Target Repurposing for Neglected Diseases

What points at this work

Incoming claims: where this work appears in other papers’ reference lists and arguments.

inferred← citeshttps://doi.org/10.1007/s00044-024-03215-1openalex-snapshot
Phenoxyalkyl cyclic and acyclic amine derivatives: what do they teach us about scaffold-based drug design?
inferred← citeshttps://doi.org/10.1016/b978-0-12-815723-7.00007-9openalex-snapshot
Plant-derived compounds against protozoan neglected diseases: toward sustainable drug development
inferred← citeshttps://doi.org/10.1016/bs.armc.2019.06.004openalex-snapshot
Shortcuts to schistosomiasis drug discovery: The state-of-the-art
inferred← citeshttps://doi.org/10.1016/j.csbj.2020.10.017openalex-snapshot
Combining structure and genomics to understand antimicrobial resistance
inferred← citeshttps://doi.org/10.1021/acs.biochem.0c00472openalex-snapshot
Expanded DNA and RNA Trinucleotide Repeats in Myotonic Dystrophy Type 1 Select Their Own Multitarget, Sequence-Selective Inhibitors
inferred← citeshttps://doi.org/10.1021/acs.jnatprod.0c00433openalex-snapshot
Production of Highly Active Antiparasitic Compounds from the Controlled Halogenation of the Arrabidaea brachypoda Crude Plant Extract
inferred← citeshttps://doi.org/10.1021/acschembio.7b00717openalex-snapshot
Enthalpy-Based Screening of Focused Combinatorial Libraries for the Identification of Potent and Selective Ligands
inferred← citeshttps://doi.org/10.1038/s41598-024-52018-2openalex-snapshot
Fragment library screening by X-ray crystallography and binding site analysis on thioredoxin glutathione reductase of Schistosoma mansoni
inferred← citeshttps://doi.org/10.1070/rcr4836openalex-snapshot
NMR screening and studies of target – ligand interactions
inferred← citeshttps://doi.org/10.1080/17460441.2019.1653849openalex-snapshot
Fragment-based screening with natural products for novel anti-parasitic disease drug discovery
inferred← citeshttps://doi.org/10.1093/jb/mvac020openalex-snapshot
Fragment-Based Drug Discovery forTrypanosoma bruceiGlycosylphosphatidylinositol-Specific Phospholipase C through Biochemical and WaterLOGSY-NMR Methods
inferred← citeshttps://doi.org/10.11606/t.9.2018.tde-26072018-160153openalex-snapshot
Aplicação de planejamento baseado na estrutura do receptor na busca de inibidores de cisteíno-proteases parasitárias (cruzaína (T. cruzi) e PCB (Leishmanioses))
inferred← citeshttps://doi.org/10.11606/t.9.2019.tde-08032019-174942openalex-snapshot
Busca por inibidores seletivos de Sirtuína 2 de T. cruzi empregando técnicas de planejamento de fármacos baseadona estrutura do receptor
inferred← citeshttps://doi.org/10.1186/s40249-018-0444-1openalex-snapshot
Innovation in neglected tropical disease drug discovery and development
inferred← citeshttps://doi.org/10.2174/0929867326666190610160534openalex-snapshot
19F-NMR in Target-based Drug Discovery
inferred← citeshttps://doi.org/10.3389/fimmu.2021.642383openalex-snapshot
Schistosomiasis Drug Discovery in the Era of Automation and Artificial Intelligence
inferred← citeshttps://doi.org/10.3389/fmicb.2018.02655openalex-snapshot
Host-Directed Drug Therapies for Neglected Tropical Diseases Caused by Protozoan Parasites
inferred← citeshttps://doi.org/10.3390/books978-3-03928-255-5openalex-snapshot
In-Cell NMR Spectroscopy
inferred← citeshttps://doi.org/10.3390/ijms20010139openalex-snapshot
Applications of In-Cell NMR in Structural Biology and Drug Discovery
inferred← citeshttps://doi.org/10.3390/molecules27041400openalex-snapshot
In Vitro Antileishmanial and Antitrypanosomal Activities of Plicataloside Isolated from the Leaf Latex of Aloe rugosifolia Gilbert & Sebsebe (Asphodelaceae)
Editorial review for independent work. ICSAC — the Institute for Complexity Science and Advanced Computing — runs a structured editorial panel for researchers publishing outside journals, and publishes on CiteStamp rails. Submission is free and goes through ORCID: icsacinstitute.org/submit.